Author Archive: BIOtechNOW Editor

Shining A Light on Lung Cancer

Shine-A-Light115x76

Lung cancer is the leading cause of cancer death in the US, taking the lives of twice as many women as breast cancer and three times as many men as prostate cancer. While a history of smoking is the main risk factor for developing lung cancer, nearly 80% of those diagnosed today were never smokers or are former smokers who quit decades ago. November is Lung Cancer Awareness Month, a time of reflection for advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The First-Ever BIO Latin America Conference a Major Success

BIO_Latin_America

The first-ever BIO Latin America Conference was a major success and will become an annual must-attend event for those doing business in the region. Rio de Janeiro, SEPTEMBER 2014 – The 2014 BIO Latin America Conference, held on September 9-11, in Rio de Janeiro, brought together the in-depth expertise vital to the growth of the biotech industry in Latin America, and provided the attendees with networking and programming not available at any other regional gathering. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Mito What???

Liz-Kennerly-115x76

Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, mitochondrial disease was virtually unheard of.  Just 10 years ago, it was considered rare. Today, according to NORD, a disease is considered rare when less than 200,000 people are affected.  Mitochondrial disease is not a single disease, but rather an entire umbrella of rare diseases.  For example, Alpers disease and Barth syndrome are very different and rare forms of mitochondrial Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Playing Detective With Checkpoint Therapies

medical_research

Three words are on the lips of everyone following new developments in cancer therapies: checkpoint inhibitor drugs. Simply put, investigators believe they have figured out a way to dismantle the mechanism used by cancer cells to stay hidden from T-cells, a type of specialized immune cell. CTLA-4 is a protein on the surface of T-cells that acts as an “off” switch for the sleuthing T-cells. It signals them to remain in a resting state, kind of like Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

NCATS SBIR Announces Funding For Biotechs and Small Business Technology Development

lab_tech

The NIH National Center for Advancing Translational Sciences (NCATS) is seeking qualified applicants for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. NCATS, which offers $17.6 million annually through these programs, has issued a call for applications for two funding opportunities: Contract funding to support small businesses and venture-backed technology development, due Nov. 5, 2014. Investigator-initiated grant funding,due Dec. 5, 2014. NCATS’ SBIR and STTR programs are engines of innovation Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,